Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2024 | Monoclonal B-cell lymphocytosis: a disease to be (or not to be)

Paolo Ghia • 7 Apr 2024
AACR 2024
Chronic Lymphocytic Leukemia Leukemia Monoclonal B-Cell Lymphocytosis

Paolo Ghia, MD, Università Vita-Salute San Raffaele, Milan, Italy, briefly discusses monoclonal B-cell lymphocytosis (MBL), a precursor condition to chronic lymphocytic leukemia (CLL), and highlights the potential value of early interception to prevent disease progression. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Paolo Ghia

MBL: biology, classification & the possibility of early interception
Andrew Rawstron et al. • 25 Mar 2024
2:20
Monoclonal B-cell lymphocytosis: at a crossroad between disease and senescence
Paolo Ghia • 8 Dec 2023
3:00
Five-year follow-up of the CAPTIVATE trial: ibrutinib retreatment in patients with CLL
Paolo Ghia • 8 Dec 2023
2:22
IMPROVE study: MRD assessment as an endpoint to define treatment length and intensity in CLL
Paolo Ghia • 7 Sep 2023

Related Videos

1:17
An ongoing Phase I/II study of sonrotoclax + zanubrutinib in patients with treatment-naive CLL/SLL
Piers Patten • 28 Apr 2024
1:51
Should MRD eradication be the goal when treating every patient with CLL?
Dima El-Sharkawi • 28 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
The content of VJHemOnc is intended for healthcare professionals